MACRODANTIN (nitrofurantoin macrocrystals) by Almatica Pharma is mechanism of action the mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Approved for urinary tract infections, enterococci, staphylococcus aureus and 4 more indications. First approved in 1970.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
MACRODANTIN is an oral nitrofuran antibiotic approved in 1970 for treatment of urinary tract infections caused by susceptible gram-negative and gram-positive bacteria including E. coli, Klebsiella, Enterobacter, and S. aureus. The drug works by being reduced to reactive intermediates that inhibit bacterial protein synthesis, energy metabolism, and nucleic acid synthesis, resulting in bactericidal activity in the urinary tract.
MACRODANTIN is in late lifecycle decline with minimal Part D spending ($25K in 2023, 106 claims), signaling a shrinking team and focus on maintenance rather than growth.
Mechanism of Action The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other acromolecules. As a result of such…
Nitrofuran Antibacterial
Worked on MACRODANTIN at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMACRODANTIN offers limited career growth opportunity due to mature lifecycle stage, minimal spend, and zero linked job openings. Roles focused on this product typically involve managing decline, cost optimization, and transition to generic alternatives rather than strategic innovation.